3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Genitourinary
2
CNS
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Neuroblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Carcinoma, Renal Cell
1
Interventions
fludarabine phosphate
7
Mycophenolic Acid
6
Peripheral Blood Stem Cell Transplantation
5
Cyclosporine
5
Whole-Body Irradiation
4
Cyclophosphamide
3
Antilymphocyte Serum
3
temsirolimus
2
Tacrolimus
2
Sunitinib
2
Radiotherapy
2
Methotrexate
2
Counseling
2
Busulfan
2
Bupropion
2
varlilumab
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
thymoglobulin
1
tanespimycin
1
sapanisertib
1
romidepsin
1
relatlimab
1
pertuzumab
1
peginterferon alfa-2a
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
alectinib
×
Other hematologic neoplasm
×
Clear all
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled